Bivalent COVID-19 Boosters Authorized for Younger Patients
On October 12, 2022, the FDA revised the Emergency Use Authorizations of the Moderna COVID-19 Vaccine, Bivalent, and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, to authorize their usage as a single booster dose at least 2 months following completion of primary or booster vaccination in younger age groups. Learn more about these recent vaccine authorization revisions.

Bivalent mRNA Vaccine Shows Superior Antibody Response
Moderna recently announced clinical data on its bivalent Omicron–containing booster, mRNA-1273.214. The data indicated that 90 days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50-mcg booster dose of mRNA-1273.214 produced a superior neutralizing antibody response against Omicron BA.1 when compared with a 50-mcg booster dose of mRNA-1273 in all participants, regardless of prior infection. Read more.

Positive Data From Trial of Omicron BA.4/BA.5–Adapted Bivalent Booster
Pfizer and BioNTech announced early data from a phase II/III clinical trial assessing the safety, tolerability, and immunogenicity of the companies' Omicron BA.4/BA.5–adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent [original and Omicron BA.4/BA.5]). A 30-mcg booster dose of the Omicron BA.4/BA.5–adapted bivalent vaccine demonstrated a substantial increase in the Omicron BA.4/BA.5 neutralizing antibody response. Read more.